MANDITORY NOTIFICATION OF TRADE IN PRONOVA BIOPHARMA

(Thomson Reuters ONE) - The primary insider, Kjetil Olsen, Senior Vice President Supply Chainin Pronova BioPharma ASA (OSE: PRON) bought, through Trols AS, 35 000shares in Pronova BioPharma ASA at a price of NOK 13.9786. Trols ASis owned 100% by Mr. Olsen. After this transaction Kjetil Olsen owns535 000 shares in Pronova BioPharma ASA.The primary insider, Elias Christensen, Legal Counsel and Secretaryof the Board of Directors in Pronova BioPharma ASA (OSE: PRON) bought3 000 shares in Pronova BioPharma ASA at a price of NOK 13.9083.After this transaction Elias Christensen owns 3 000 shares in PronovaBioPharma ASA.This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.

Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: hugin
Datum: 13.11.2009 - 15:54 Uhr
Sprache: Deutsch
News-ID 8376
Anzahl Zeichen: 0

contact information:
Town:

London

Kategorie:

Business News

Diese Pressemitteilung wurde bisher 406 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"MANDITORY NOTIFICATION OF TRADE IN PRONOVA BIOPHARMA"
steht unter der journalistisch-redaktionellen Verantwortung von

Pronova BioPharma ASA (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).

Presentation at the SEB Investor Conference in Copenhagen ...

TAK-085 Entered into Phase 3 Clinical Programs ...

December 14, 2009, Osaka, Japan and Lysaker, Norway --- Takeda Pharmaceutical Company Limited (Osaka, Japan, "Takeda") and Pronova BioPharma ASA (OSE: PRON.OL) (Lysaker, Norway, "Pronova") today announced that the advancement of T ...

Financial calender 2010 for Pronova BioPharma ASA ...

FINANCIAL CALENDAR 2010 Pronova BioPharma ASA (PRON) Lysaker, 7 December 2009: 12 February 2010: FY 2009 Results 7 May 2010: Results 1Q 2010 7 May 2010: Annual General Meeting 13 August 2010: Results 2Q 2010 12 November 2010: Results 3Q 2010 Al ...

Alle Meldungen von Pronova BioPharma ASA